This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Equol
Accession Number
DB11674
Type
Small Molecule
Groups
Investigational
Description

Equol has been used in trials studying the treatment of Breast Cancer.

Structure
Thumb
Synonyms
  • S-equol
Categories
UNII
2T6D2HPX7Q
CAS number
531-95-3
Weight
Average: 242.2699
Monoisotopic: 242.094294314
Chemical Formula
C15H14O3
InChI Key
ADFCQWZHKCXPAJ-GFCCVEGCSA-N
InChI
InChI=1S/C15H14O3/c16-13-4-1-10(2-5-13)12-7-11-3-6-14(17)8-15(11)18-9-12/h1-6,8,12,16-17H,7,9H2/t12-/m1/s1
IUPAC Name
(3S)-3-(4-hydroxyphenyl)-3,4-dihydro-2H-1-benzopyran-7-ol
SMILES
OC1=CC=C(C=C1)[C@H]1COC2=C(C1)C=CC(O)=C2

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UEstrogen receptor beta
agonist
Human
USex hormone-binding globulinNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Equol.Investigational
19-norandrostenedioneThe serum concentration of 19-norandrostenedione can be increased when it is combined with Equol.Experimental, Illicit
5-androstenedioneThe serum concentration of 5-androstenedione can be increased when it is combined with Equol.Experimental, Illicit
AbciximabEquol may decrease the anticoagulant activities of Abciximab.Approved
AceclofenacAceclofenac may increase the thrombogenic activities of Equol.Approved, Investigational
AcenocoumarolEquol may decrease the anticoagulant activities of Acenocoumarol.Approved, Investigational
Acetylsalicylic acidAcetylsalicylic acid may increase the thrombogenic activities of Equol.Approved, Vet Approved
AlclometasoneThe serum concentration of Alclometasone can be increased when it is combined with Equol.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Equol.Experimental, Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be increased when it is combined with Equol.Experimental, Investigational
AmcinonideThe serum concentration of Amcinonide can be increased when it is combined with Equol.Approved
AminophyllineThe serum concentration of Aminophylline can be increased when it is combined with Equol.Approved
Aminosalicylic AcidAminosalicylic Acid may increase the thrombogenic activities of Equol.Approved
AnastrozoleThe therapeutic efficacy of Anastrozole can be decreased when used in combination with Equol.Approved, Investigational
AncrodEquol may decrease the anticoagulant activities of Ancrod.Approved, Investigational
AndrostenedioneThe serum concentration of Androstenedione can be increased when it is combined with Equol.Experimental, Illicit
AnecortaveThe serum concentration of Anecortave can be increased when it is combined with Equol.Investigational
anecortave acetateThe serum concentration of anecortave acetate can be increased when it is combined with Equol.Investigational
Anthrax immune globulin humanEquol may increase the thrombogenic activities of Anthrax immune globulin human.Approved
AntipyrineAntipyrine may increase the thrombogenic activities of Equol.Approved, Investigational
Antithrombin III humanEquol may decrease the anticoagulant activities of Antithrombin III human.Approved
AntrafenineAntrafenine may increase the thrombogenic activities of Equol.Approved
ApixabanEquol may decrease the anticoagulant activities of Apixaban.Approved
ArdeparinEquol may decrease the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanEquol may decrease the anticoagulant activities of Argatroban.Approved, Investigational
Ascorbic acidThe serum concentration of Equol can be increased when it is combined with Vitamin C.Approved, Nutraceutical
AtamestaneThe serum concentration of Atamestane can be increased when it is combined with Equol.Investigational
BalsalazideBalsalazide may increase the thrombogenic activities of Equol.Approved, Investigational
BecaplerminEquol may decrease the anticoagulant activities of Becaplermin.Approved, Investigational
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Equol.Approved, Vet Approved
BivalirudinEquol may decrease the anticoagulant activities of Bivalirudin.Approved, Investigational
BromfenacBromfenac may increase the thrombogenic activities of Equol.Approved
BufexamacBufexamac may increase the thrombogenic activities of Equol.Approved, Experimental
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Equol.Approved
Capromab pendetideEquol may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
CapsaicinCapsaicin may increase the thrombogenic activities of Equol.Approved
CarprofenCarprofen may increase the thrombogenic activities of Equol.Approved, Vet Approved, Withdrawn
CelecoxibCelecoxib may increase the thrombogenic activities of Equol.Approved, Investigational
CertoparinEquol may decrease the anticoagulant activities of Certoparin.Approved, Investigational
Chenodeoxycholic acidThe therapeutic efficacy of Chenodeoxycholic acid can be decreased when used in combination with Equol.Approved
ChlorphenesinChlorphenesin may increase the thrombogenic activities of Equol.Approved, Vet Approved, Withdrawn
Choline magnesium trisalicylateCholine magnesium trisalicylate may increase the thrombogenic activities of Equol.Approved
CiclesonideThe serum concentration of Ciclesonide can be increased when it is combined with Equol.Approved, Investigational
CimicoxibCimicoxib may increase the thrombogenic activities of Equol.Investigational
CisplatinCisplatin may increase the thrombogenic activities of Equol.Approved
ClobetasolThe serum concentration of Clobetasol can be increased when it is combined with Equol.Approved, Investigational
Clobetasol propionateThe serum concentration of Clobetasol propionate can be increased when it is combined with Equol.Approved
ClobetasoneThe serum concentration of Clobetasone can be increased when it is combined with Equol.Approved
ClocortoloneThe serum concentration of Clocortolone can be increased when it is combined with Equol.Approved
Clodronic AcidClodronic Acid may increase the thrombogenic activities of Equol.Approved, Investigational, Vet Approved
Conestat alfaEquol may increase the thrombogenic activities of Conestat alfa.Approved, Investigational
Cortexolone 17α-propionateThe serum concentration of Cortexolone 17α-propionate can be increased when it is combined with Equol.Investigational
CorticosteroneThe serum concentration of Corticosterone can be increased when it is combined with Equol.Experimental
Cortisone acetateThe serum concentration of Cortisone acetate can be increased when it is combined with Equol.Approved, Investigational
Dabigatran etexilateEquol may decrease the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinEquol may decrease the anticoagulant activities of Dalteparin.Approved
DanaparoidEquol may decrease the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanEquol may decrease the anticoagulant activities of Darexaban.Investigational
DeflazacortThe serum concentration of Deflazacort can be increased when it is combined with Equol.Approved, Investigational
DesirudinEquol may decrease the anticoagulant activities of Desirudin.Approved
DesonideThe serum concentration of Desonide can be increased when it is combined with Equol.Approved, Investigational
DesoximetasoneThe serum concentration of Desoximetasone can be increased when it is combined with Equol.Approved
Desoxycorticosterone acetateThe serum concentration of Desoxycorticosterone acetate can be increased when it is combined with Equol.Approved
Desoxycorticosterone PivalateThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Equol.Experimental, Vet Approved
Dexamethasone isonicotinateThe serum concentration of Dexamethasone isonicotinate can be increased when it is combined with Equol.Vet Approved
DexibuprofenDexibuprofen may increase the thrombogenic activities of Equol.Approved, Investigational
DexketoprofenDexketoprofen may increase the thrombogenic activities of Equol.Approved, Investigational
DextranEquol may decrease the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DicoumarolEquol may decrease the anticoagulant activities of Dicoumarol.Approved
DiflorasoneThe serum concentration of Diflorasone can be increased when it is combined with Equol.Approved
DiflunisalDiflunisal may increase the thrombogenic activities of Equol.Approved, Investigational
DifluocortoloneThe serum concentration of Difluocortolone can be increased when it is combined with Equol.Approved, Investigational, Withdrawn
DifluprednateThe serum concentration of Difluprednate can be increased when it is combined with Equol.Approved
DrospirenoneDrospirenone may increase the thrombogenic activities of Equol.Approved
DroxicamDroxicam may increase the thrombogenic activities of Equol.Withdrawn
DyphyllineThe serum concentration of Dyphylline can be increased when it is combined with Equol.Approved
Edetic AcidEquol may decrease the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanEquol may decrease the anticoagulant activities of Edoxaban.Approved
EnoxaparinEquol may decrease the anticoagulant activities of Enoxaparin.Approved
EquileninThe serum concentration of Equilenin can be increased when it is combined with Equol.Experimental
EquilinThe serum concentration of Equilin can be increased when it is combined with Equol.Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Equol.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be increased when it is combined with Equol.Approved
EtanerceptEtanercept may increase the thrombogenic activities of Equol.Approved, Investigational
Ethyl biscoumacetateEquol may decrease the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacEtodolac may increase the thrombogenic activities of Equol.Approved, Investigational, Vet Approved
EtoricoxibEtoricoxib may increase the thrombogenic activities of Equol.Approved, Investigational
ExemestaneThe therapeutic efficacy of Exemestane can be decreased when used in combination with Equol.Approved, Investigational
FenoprofenFenoprofen may increase the thrombogenic activities of Equol.Approved
Ferulic acidEquol may decrease the anticoagulant activities of Ferulic acid.Experimental
FluasteroneThe serum concentration of Fluasterone can be increased when it is combined with Equol.Investigational
FludrocortisoneThe serum concentration of Fludrocortisone can be increased when it is combined with Equol.Approved, Investigational
FluindioneEquol may decrease the anticoagulant activities of Fluindione.Approved, Investigational
FlumethasoneThe serum concentration of Flumethasone can be increased when it is combined with Equol.Approved, Vet Approved
FlunisolideThe serum concentration of Flunisolide can be increased when it is combined with Equol.Approved, Investigational
Fluocinolone AcetonideThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Equol.Approved, Investigational, Vet Approved
FluocinonideThe serum concentration of Fluocinonide can be increased when it is combined with Equol.Approved, Investigational
FluocortoloneThe serum concentration of Fluocortolone can be increased when it is combined with Equol.Approved, Withdrawn
FluorometholoneThe serum concentration of Fluorometholone can be increased when it is combined with Equol.Approved, Investigational
FluprednideneThe serum concentration of Fluprednidene can be increased when it is combined with Equol.Approved, Withdrawn
FluprednisoloneThe serum concentration of Fluprednisolone can be increased when it is combined with Equol.Approved
FlurandrenolideThe serum concentration of Flurandrenolide can be increased when it is combined with Equol.Approved
FlurbiprofenFlurbiprofen may increase the thrombogenic activities of Equol.Approved, Investigational
FluticasoneThe serum concentration of Fluticasone can be increased when it is combined with Equol.Approved, Experimental, Investigational
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Equol.Approved
FondaparinuxEquol may decrease the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
FormestaneThe serum concentration of Formestane can be increased when it is combined with Equol.Approved, Investigational, Withdrawn
GabexateEquol may decrease the anticoagulant activities of Gabexate.Investigational
GanciclovirThe serum concentration of Ganciclovir can be increased when it is combined with Equol.Approved, Investigational
GinsengGinseng may increase the thrombogenic activities of Equol.Approved, Investigational, Nutraceutical
HalcinonideThe serum concentration of Halcinonide can be increased when it is combined with Equol.Approved, Investigational, Withdrawn
HE3286The serum concentration of HE3286 can be increased when it is combined with Equol.Investigational
HeparinEquol may decrease the anticoagulant activities of Heparin.Approved, Investigational
Human C1-esterase inhibitorEquol may increase the thrombogenic activities of Human C1-esterase inhibitor.Approved
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Equol.Approved, Investigational
IcosapentIcosapent may increase the thrombogenic activities of Equol.Approved, Nutraceutical
IdraparinuxEquol may decrease the anticoagulant activities of Idraparinux.Investigational
IndomethacinIndomethacin may increase the thrombogenic activities of Equol.Approved, Investigational
IstaroximeThe serum concentration of Istaroxime can be increased when it is combined with Equol.Investigational
KetoprofenKetoprofen may increase the thrombogenic activities of Equol.Approved, Vet Approved
LenalidomideEquol may increase the thrombogenic activities of Lenalidomide.Approved
LepirudinEquol may decrease the anticoagulant activities of Lepirudin.Approved
LetaxabanEquol may decrease the anticoagulant activities of Letaxaban.Investigational
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Equol.Approved
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Equol.Approved, Vet Approved
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Equol.Approved
LornoxicamLornoxicam may increase the thrombogenic activities of Equol.Approved, Investigational
LoteprednolThe serum concentration of Loteprednol can be increased when it is combined with Equol.Approved
LumiracoxibLumiracoxib may increase the thrombogenic activities of Equol.Approved, Investigational
Magnesium salicylateMagnesium salicylate may increase the thrombogenic activities of Equol.Approved
ME-609The serum concentration of ME-609 can be increased when it is combined with Equol.Investigational
Meclofenamic acidMeclofenamic acid may increase the thrombogenic activities of Equol.Approved, Vet Approved
MedrysoneThe serum concentration of Medrysone can be increased when it is combined with Equol.Approved
Mefenamic acidMefenamic acid may increase the thrombogenic activities of Equol.Approved
MelagatranEquol may decrease the anticoagulant activities of Melagatran.Experimental
MelengestrolThe serum concentration of Melengestrol can be increased when it is combined with Equol.Vet Approved
MeloxicamMeloxicam may increase the thrombogenic activities of Equol.Approved, Vet Approved
MesalazineMesalazine may increase the thrombogenic activities of Equol.Approved
MometasoneThe serum concentration of Mometasone can be increased when it is combined with Equol.Approved, Vet Approved
MorniflumateMorniflumate may increase the thrombogenic activities of Equol.Approved
NabumetoneNabumetone may increase the thrombogenic activities of Equol.Approved
NadroparinEquol may decrease the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatEquol may decrease the anticoagulant activities of Nafamostat.Approved, Investigational
NCX 1022The serum concentration of NCX 1022 can be increased when it is combined with Equol.Investigational
NepafenacNepafenac may increase the thrombogenic activities of Equol.Approved, Investigational
Niflumic AcidNiflumic Acid may increase the thrombogenic activities of Equol.Approved
NimesulideNimesulide may increase the thrombogenic activities of Equol.Approved, Investigational, Withdrawn
Oleoyl-estroneThe serum concentration of Oleoyl-estrone can be increased when it is combined with Equol.Investigational
OspemifeneThe risk or severity of adverse effects can be increased when Equol is combined with Ospemifene.Approved, Investigational
OtamixabanEquol may decrease the anticoagulant activities of Otamixaban.Investigational
OxaprozinOxaprozin may increase the thrombogenic activities of Equol.Approved
ParamethasoneThe serum concentration of Paramethasone can be increased when it is combined with Equol.Approved
ParecoxibParecoxib may increase the thrombogenic activities of Equol.Approved
Pentaerythritol TetranitrateEquol may decrease the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateEquol may decrease the anticoagulant activities of Pentosan Polysulfate.Approved
PhenindioneEquol may decrease the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonEquol may decrease the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazonePhenylbutazone may increase the thrombogenic activities of Equol.Approved, Vet Approved
PiroxicamPiroxicam may increase the thrombogenic activities of Equol.Approved, Investigational
PomalidomidePomalidomide may increase the thrombogenic activities of Equol.Approved
Potassium CitrateEquol may decrease the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Equol.Approved, Investigational, Nutraceutical
Prasterone sulfateThe serum concentration of Prasterone sulfate can be increased when it is combined with Equol.Investigational
PrednicarbateThe serum concentration of Prednicarbate can be increased when it is combined with Equol.Approved, Investigational
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Equol.Approved, Vet Approved
PregnenoloneThe serum concentration of Pregnenolone can be increased when it is combined with Equol.Approved, Experimental, Investigational
Protein CEquol may decrease the anticoagulant activities of Protein C.Approved
Protein S humanEquol may decrease the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeEquol may decrease the anticoagulant activities of Protocatechualdehyde.Approved
ResveratrolResveratrol may increase the thrombogenic activities of Equol.Approved, Experimental, Investigational
ReviparinEquol may decrease the anticoagulant activities of Reviparin.Approved, Investigational
RimexoloneThe serum concentration of Rimexolone can be increased when it is combined with Equol.Approved
RivaroxabanEquol may decrease the anticoagulant activities of Rivaroxaban.Approved
RofecoxibRofecoxib may increase the thrombogenic activities of Equol.Approved, Investigational, Withdrawn
RopiniroleEquol may increase the excretion rate of Ropinirole which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
SalsalateSalsalate may increase the thrombogenic activities of Equol.Approved
SeliciclibSeliciclib may increase the thrombogenic activities of Equol.Investigational
Sodium CitrateEquol may decrease the anticoagulant activities of Sodium Citrate.Approved, Investigational
SomatotropinThe therapeutic efficacy of Somatotropin can be decreased when used in combination with Equol.Approved, Investigational
SulodexideEquol may decrease the anticoagulant activities of Sulodexide.Approved, Investigational
SuprofenSuprofen may increase the thrombogenic activities of Equol.Approved, Withdrawn
TalniflumateTalniflumate may increase the thrombogenic activities of Equol.Approved
TenoxicamTenoxicam may increase the thrombogenic activities of Equol.Approved
ThalidomideEquol may increase the thrombogenic activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe serum concentration of Theophylline can be increased when it is combined with Equol.Approved
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Equol.Approved
Tiaprofenic acidTiaprofenic acid may increase the thrombogenic activities of Equol.Approved
TipranavirEquol may increase the dermatologic adverse activities of Tipranavir.Approved, Investigational
TixocortolThe serum concentration of Tixocortol can be increased when it is combined with Equol.Approved, Withdrawn
TolmetinTolmetin may increase the thrombogenic activities of Equol.Approved
TriamcinoloneThe serum concentration of Triamcinolone can be increased when it is combined with Equol.Approved, Vet Approved
TroxerutinEquol may decrease the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe serum concentration of Ulobetasol can be increased when it is combined with Equol.Approved
Ursodeoxycholic acidThe therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Equol.Approved, Investigational
ValaciclovirThe serum concentration of Valaciclovir can be increased when it is combined with Equol.Approved, Investigational
ValdecoxibValdecoxib may increase the thrombogenic activities of Equol.Approved, Investigational, Withdrawn
WarfarinEquol may decrease the anticoagulant activities of Warfarin.Approved
XimelagatranEquol may decrease the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0002209
KEGG Compound
C14131
PubChem Compound
91469
PubChem Substance
347828042
ChemSpider
82594
BindingDB
50410528
ChEBI
34741
ChEMBL
CHEMBL198877
Wikipedia
Equol

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingTreatmentCancer, Breast1
1CompletedNot AvailableHealthy Volunteers1
1CompletedBasic ScienceHealthy Volunteers1
1, 2RecruitingTreatmentAlzheimer's Disease (AD)1
2CompletedTreatmentBenign Prostatic Hyperplasia (BPH)1
2CompletedTreatmentMenopause1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0445 mg/mLALOGPS
logP2.91ALOGPS
logP3.19ChemAxon
logS-3.7ALOGPS
pKa (Strongest Acidic)9.63ChemAxon
pKa (Strongest Basic)-4.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area49.69 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity68.96 m3·mol-1ChemAxon
Polarizability25.81 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as isoflavanols. These are polycyclic compounds containing a hydroxylated isoflavan skeleton.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Isoflavonoids
Sub Class
Isoflavans
Direct Parent
Isoflavanols
Alternative Parents
Hydroxyisoflavonoids / 1-benzopyrans / Alkyl aryl ethers / 1-hydroxy-2-unsubstituted benzenoids / Benzene and substituted derivatives / Oxacyclic compounds / Hydrocarbon derivatives
Substituents
Hydroxyisoflavonoid / Isoflavanol / Chromane / Benzopyran / 1-benzopyran / Alkyl aryl ether / 1-hydroxy-2-unsubstituted benzenoid / Phenol / Monocyclic benzene moiety / Benzenoid
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
hydroxyisoflavans (CHEBI:34741) / isoflavans, Isoflavanes (C14131)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Nuclear hormone receptor. Binds estrogens with an affinity similar to that of ESR1, and activates expression of reporter genes containing estrogen response elements (ERE) in an estrogen-dependent m...
Gene Name
ESR2
Uniprot ID
Q92731
Uniprot Name
Estrogen receptor beta
Molecular Weight
59215.765 Da
References
  1. Mueller SO, Simon S, Chae K, Metzler M, Korach KS: Phytoestrogens and their human metabolites show distinct agonistic and antagonistic properties on estrogen receptor alpha (ERalpha) and ERbeta in human cells. Toxicol Sci. 2004 Jul;80(1):14-25. Epub 2004 Apr 14. [PubMed:15084758]
  2. Setchell KD, Clerici C, Lephart ED, Cole SJ, Heenan C, Castellani D, Wolfe BE, Nechemias-Zimmer L, Brown NM, Lund TD, Handa RJ, Heubi JE: S-equol, a potent ligand for estrogen receptor beta, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. Am J Clin Nutr. 2005 May;81(5):1072-9. [PubMed:15883431]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Androgen binding
Specific Function
Functions as an androgen transport protein, but may also be involved in receptor mediated processes. Each dimer binds one molecule of steroid. Specific for 5-alpha-dihydrotestosterone, testosterone...
Gene Name
SHBG
Uniprot ID
P04278
Uniprot Name
Sex hormone-binding globulin
Molecular Weight
43778.755 Da
References
  1. Hong H, Branham WS, Ng HW, Moland CL, Dial SL, Fang H, Perkins R, Sheehan D, Tong W: Human sex hormone-binding globulin binding affinities of 125 structurally diverse chemicals and comparison with their binding to androgen receptor, estrogen receptor, and alpha-fetoprotein. Toxicol Sci. 2015 Feb;143(2):333-48. doi: 10.1093/toxsci/kfu231. Epub 2014 Oct 27. [PubMed:25349334]

Drug created on October 20, 2016 14:38 / Updated on August 02, 2018 06:27